| TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial CF Burant, P Viswanathan, J Marcinak, C Cao, M Vakilynejad, B Xie, ... The Lancet 379 (9824), 1403-1411, 2012 | 267 | 2012 |
| dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy DC Metz, M Vakily, T Dixit, D Mulford Alimentary pharmacology & therapeutics 29 (9), 928-937, 2009 | 153 | 2009 |
| Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled … M Vakily, W Zhang, J Wu, SN Atkinson, D Mulford Current medical research and opinion 25 (3), 627-638, 2009 | 128 | 2009 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK‐875: results from a double‐blind, placebo‐controlled single oral dose rising … H Naik, M Vakilynejad, J Wu, P Viswanathan, N Dote, T Higuchi, E Leifke The Journal of Clinical Pharmacology 52 (7), 1007-1016, 2012 | 104 | 2012 |
| A multiple‐ascending‐dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK‐875, in subjects with type 2 diabetes E Leifke, H Naik, J Wu, P Viswanathan, D Demanno, M Kipnes, ... Clinical Pharmacology & Therapeutics 92 (1), 29-39, 2012 | 95 | 2012 |
| Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs R Mehvar, DR Brocks, M Vakily Clinical pharmacokinetics 41, 533-558, 2002 | 95 | 2002 |
| Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump … RD Lee, M Vakily, D Mulford, J Wu, SN Atkinson Alimentary pharmacology & therapeutics 29 (8), 824-833, 2009 | 85 | 2009 |
| Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methylcellulose matrices SP Duddu, M Vakilynejad, F Jamali, DJW Grant Pharmaceutical research 10, 1648-1653, 1993 | 60 | 1993 |
| Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury FS Wolenski, AZX Zhu, M Johnson, S Yu, Y Moriya, T Ebihara, ... Toxicological Sciences 157 (1), 50-61, 2017 | 56 | 2017 |
| The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats M Vakily, B Corrigan, F Jamali Pharmaceutical research 12, 1652-1657, 1995 | 55 | 1995 |
| Prediction of nephropathy in type 2 diabetes: an analysis of the ACCORD trial applying machine learning techniques V Rodriguez‐Romero, RF Bergstrom, BS Decker, G Lahu, M Vakilynejad, ... Clinical and translational science 12 (5), 519-528, 2019 | 53 | 2019 |
| Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis M Vakily, F Amer, MJ Kukulka, N Andhivarothai The Journal of Clinical Pharmacology 45 (10), 1179-1186, 2005 | 52 | 2005 |
| Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape E Schuck, T Bohnert, A Chakravarty, V Damian-Iordache, C Gibson, ... The AAPS journal 17, 462-473, 2015 | 50 | 2015 |
| Lansoprazole regimens that sustain intragastric pH> 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages DC Metz, F Amer, B Hunt, M Vakily, MJ Kukulka, N Samra Alimentary pharmacology & therapeutics 23 (7), 985-995, 2006 | 48 | 2006 |
| Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double … M Vakily, RD Lee, J Wu, L Gunawardhana, D Mulford Clinical drug investigation 29, 35-50, 2009 | 41 | 2009 |
| Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents M Vakily, R Mehvar, D Brocks Annals of pharmacotherapy 36 (4), 693-701, 2002 | 34 | 2002 |
| Rapid, sensitive and direct chiral high-performance liquid chromatographic method for ketoprofen enantiomers R Lovlin, M Vakily, F Jamali Journal of Chromatography B: Biomedical Sciences and Applications 679 (1-2 …, 1996 | 34 | 1996 |
| Human pharmacokinetics of tiaprofenic acid after regular and sustained release formulations: lack of chiral inversion and stereoselective release M Vakily, F Jamali Journal of pharmaceutical sciences 83 (4), 495-498, 1994 | 30 | 1994 |
| S1095 the pharmacokinetics of TAK-390mr 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis MD Mayer, M Vakily, G Witt, DJ Mulford Gastroenterology 4 (134), A-176, 2008 | 29 | 2008 |
| Inclusion complexation of heptakis(2,6‐di‐o‐ethyl)‐β‐cyclodextrin with tiaprofenic acid: Pharmacokinetic consequences of a pH‐dependent release and … M Vakily, FM Pasutto, M Daneshtalab, F Jamali Journal of pharmaceutical sciences 84 (8), 1014-1019, 1995 | 25 | 1995 |
Fakhreddin JamaliUniversity of AlbertaVerified email at ualberta.ca
